美国Dynavax Technologies 
流感疫苗 Dynavax技术公司是一家临床阶段的生物制药公司，致力于发现和开发新产品，以预防和治疗感染性疾病。

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases. Our clinical-stage product candidates include:

Phase 3 HEPLISAV ™ Hepatitis B Vaccine
Phase 1 Hepatitis C Therapy
Phase 1 Hepatitis B Therapy
In addition, we are developing a preclinical Universal Flu vaccine and programs partnered with pharmaceutical companies, including AstraZeneca and GlaxoSmithKline.

Our European subsidiary Rhein Biotech manufactures hepatitis B surface antigen for HEPLISAV. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.